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OBJECTIVE
Persons with diabetes but no chronic kidney disease (CKD) and without albuminuria
have the sameage-relateddecline in kidney function as thebackgroundpopulation.
Whether this also applies following moderate loss in kidney function is unknown.
We quantified the impact of albuminuria status on the development of estimated
glomerular filtration rate (eGFR) trajectories following CKD stage 3 (CKD3) and as-
sessed potential heterogeneous development patterns among the subgroup with
normoalbuminuria.
RESEARCH DESIGN AND METHODS
We used repeated clinical measures during up to 16 years of follow-up in 935
persons with type 1 diabetes and 1,984 with type 2 diabetes. Trajectories of eGFR
by diabetes type and albuminuria status following CKD3 were estimated with
spline mixed-effects models with adjustment for relevant confounders. Latent
class trajectory modeling was used to find distinct patterns of eGFR development
in the subgroups with normoalbuminuria.
RESULTS
Mean annual declines in eGFR for normo-, micro- and macroalbuminuria the first
10 years following CKD3 were 1.9, 2.3, and 3.3 mL/min/1.73 m2 in type 1 diabetes
and 1.9, 2.1, and 3.0 in type 2 diabetes, respectively. For normoalbuminuria, two
distinct eGFR patterns were found, one with accelerated declining eGFR levels.
This specific progression pattern was associated with less use of lipid-lowering treat-
ment, renin-angiotensin system blockers, and other antihypertensive treatment.
CONCLUSIONS
Our results support a diabetes-dependent decline in kidney function without
albuminuria following CKD3, with a subgroup showing a progressive decline.
Furthermore, this group seems to be undertreated in terms of cardioprotective
and renal protective treatment and suggests that increased attention should be
drawn to normoalbuminuric diabetic kidney disease.
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Chronic kidney disease (CKD) is affecting
approximately 10% of the global popu-
lation (1), with diabetes as the leading
risk factor for renal impairment. CKD is
usually progressive and may lead to end-
stage kidney disease (ESKD), also known
as kidney failure.
General improvements in medical care
have reduced the prevalence of diabetes-
related complications such as myocardial
infarction and stroke. However, despite
intensified treatment of hypertension and
increased use of renin-angiotensin system
(RAS) blockers, the frequency of ESKD in
diabetes remain virtually unchanged (2).
With the growing number of people with
diabetes, this could have a massive effect
on the number of cases of ESKD.
Diabetic kidney disease is silent until
the very late stages. Moderate to severe
stages of CKD are measured by the
estimated glomerular filtration rate
(eGFR) (3), and studies have shown
that already from CKD stage 3 (CKD3),
corresponding to eGFR ,60 mL/min/
1.73 m2, risk of cardiovascular disease
and mortality is increased (4).
Another marker of kidney damage is
albuminuria, and it is a common assump-
tion that in persons with diabetes, a de-
cline in kidney function is preceded by
albuminuria. However, a substantial num-
ber of persons entering CKD3 will have
normoalbuminuria (3,5,6) and, especially
in type 2 diabetes, the prevalence of this
stage (CKD3 with normoalbuminuria) is
increasing (6). It is debatedwhether eGFR
development in CKD3 with normoalbumi-
nuria reflects normal age-related decline
in renal function, diabetic kidney disease
with previous albuminuria normalized by
antihypertensive treatment, or a new
phenotype of kidney disease in diabetes. A
better understanding of disease progres-
sion in this group of people is imperative
for optimal risk stratification and subse-
quent clinical treatment.
A linear decline in eGFR over time is
often assumed (7), but while this may be
true in some groups of persons with
diabetes, others have nonlinear patterns
of development (8,9). For the ability to
detect true nonlinear development pat-
terns, multiple repetitive measurements
of eGFRs over longer periods of time are
needed.
The aim of this study was to assess the
impact of albuminuria status on the de-
velopment over time in eGFR in a large
population of people with diabetes
entering CKD3 and with multiple sub-
sequent clinical visits over a long period
of follow-up. Furthermore, we aimed to
study the shape of the eGFR curve with a
specific aim of assessing potential het-
erogeneity in eGFR development among
persons with diabetes and normoalbu-
minuria after entering CKD3.
RESEARCH DESIGN AND METHODS
Study Design and Participants
The study is based on 3,343 adults with
type 1 diabetes or type 2 diabetes treated
at Steno Diabetes Center Copenhagen in
the period 1 January 2001 to 31 May
2017 with at least one measurement of
an eGFR in CKD3 (eGFR ,60 mL/min/
1.73 m2). Clinical examinations prior to
the first recorded low eGFR measure-
ment in CKD3 were not considered. We
excluded persons with no or with an
implausible date of diabetes diagnosis
(n = 40 [1.1%]). Another 384 (11.5%)
persons were excluded due to no mea-
surements of serum creatinine following
their first low eGFR measurement, leav-
ing 2,919 persons with diabetes with a
total of 28,387 clinical measurements for
analysis.
According to Danish law, ethics ap-
proval and patient consent are not re-
quired for registry-based studies. Access
to and use of the described data are
approved by the Danish Data Protection
Agency.
Measurements and Definitions
For separation of type 1 from type 2
diabetes, type 1 diabetes was clinically
diagnosed based on phenotype and in
accordance with the Danish National
Diabetes Quality Database requirements
as previously described (10).
Because date of diabetes diagnosis is
only recorded as year of diagnosis, we set
the date to 1 July of that year. However,
if the person had a clinical measurement
of serum creatinine before 1 July that
year, the date of diabetes diagnosis
was changed to the date of the clinical
measurement.
Urinary albumin excretion ratio was
measured in 24-h sterile urine collections
or from the urinary albumin-to-creatinine
ratio (UACR)measuredona singlefirst-void
urine sample. Urine creatinine, urine albu-
min, and serum creatinine concentra-
tions were determined by an enzymatic
method (Hitachi 912 system). During
2010, the study laboratory gradually
implemented the Vitros 5600 Integrated
System (Ortho Clinical Diagnostics, Illkirch
Cedex, France). All Vitros values were
converted to correspond with Hitachi val-
ues. Albuminuria status was classified
as normoalbuminuria (UACR ,30 mg/g),
microalbuminuria (30–299 mg/g), or
macroalbuminuria ($300 mg/g).
The Chronic Kidney Disease Epidemi-
ology Collaboration standard equation
(11) was used to calculate eGFR, as rec-
ommended in the 2013 guidelines from
the Kidney Disease: Improving Global
Outcomes (KDIGO) foundation. CKD3
was defined as eGFR,60 mL/min/1.73
m2 according to guidelines (3).
Brachial systolic and diastolic blood
pressure was measured twice with an
automated oscillometric blood pressure
recorder, and the average of the mea-
surements was used. For persons with
possible white-coat hypertension, home
blood pressure monitoring was offered
according to guidelines (12). HbA1c was
determinedby standard high-performance
liquid chromatography (normal range
4.1–6.4% [21–46 mmol/mol]) (Variant;
Bio-Rad Laboratories, Munich, Ger-
many). Total cholesterol, HDL choles-
terol, and triglycerides were measured
by using the Hitachi 912 system (Roche
Diagnostics, Mannheim, Germany). LDL
cholesterol was calculated by using the
Friedewald equation (13).
Smoking was defined as current
smoker (yes/no). RAS blockers were de-
fined as any use of ACE inhibitors or
angiotensin II receptor blockers (yes/no).
Retinopathy status was assessed from
retinal photographs taken through di-
lated pupils. Grading was based on the
worse eye and classified according to the
international clinical diabetic retinopathy
severity scale into three groups as follows:
no apparent retinopathy, mild/moderate
retinopathy, or severe retinopathy (14).
Statistical Analysis
Persons with diabetes were followed
from their first recorded low eGFR
(,60 mL/min/1.73 m2) (baseline) until
their last clinical examination. Trajecto-
ries of eGFR development over time after
baseline were estimated by mixed-
effects models with a person-specific
random intercept and slope. The models
were fitted using the lmer function, and
95% CIs for the mean curves were cal-
culated with bootstrapping (1,000 re-
peats) using the bootMer function in
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the lme4 package (15). We used a two-step
approach for confounder adjustment,
first adjusting for the nonmodifiable
factors sex, age at diabetes diagnosis,
diabetes duration, and calendar time
(model 1) and then additionally adjusting
for use of RAS blockers, retinopathy
status, HbA1c, antihypertensive treat-
ment, blood pressure, current smok-
ing, and lipid-lowering treatment (model
2). Interaction between time and albu-
minuria status was included and tested
in model 1. We further tested for non-
linearity in the eGFR development by
comparing a model with a linear term
for timewith amodel using natural cubic
splines to model the association with
time. For the spline model, knots were
set at the quartiles of the time distribu-
tion. In model 2, interaction between
time and use of RAS blockers was tested.
Except for sex and age at diagnosis, all
factors were included as time-varying
covariates, e.g., a person with normoal-
buminuria at baseline who subsequently
progresses to microalbuminuria will con-
tribute with eGFR measurements first in
the normoalbuminuric group and later
in the microalbuminuric group. Prior to
analysis, eGFR was log transformed to
fulfill the assumption of normally distrib-
uted model residuals. The analysis was
stratified by diabetes type.
Because a clinical classification of
moderate loss of kidney function
(CKD3) may result in intensified treat-
ment, we repeated the analysis follow-
ing persons from an eGFR,70 mL/min/
1.73 m2. A total of 978 persons with
type 1 and 2,098 with type 2 diabetes
were included in this sensitivity analysis.
In the subset of persons with normoal-
buminuria who were also without albumin-
uria at baseline, we further investigated
heterogeneity in the eGFR trajectories, us-
ing latent class trajectory modeling (LCTM)
(16). LCTM is a data-driven hypothesis-
free statistical approach for identifying
clusters of distinct developmental patterns
of a longitudinal measured marker. We
adjusted for calendar time and modeled
time since baseline with natural cubic
splines including a person-specific random
intercept and slope. The models were fit-
tedusing thehlme function in theRpackage
lcmm (17). The optimal number of latent
classes was determined using the Bayesian
information criterion (smaller is better), rel-
ative entropy, mean posterior probability
of class membership, group size of the
trajectories, and interpretability (18). Sol-
utions with two, three, four, and five la-
tent classes were tested. The analysis was
based on 397 with type 1 and 857 with
type 2 diabetes and stratified by diabetes
type.
Statistical analyses were performed
in R, version 3.4.1 (http://www.r-project
.org/).
RESULTS
The study population comprised 935
persons with type 1 diabetes with 10,110
clinical measurements with a median
follow-up time of 5.1 years (interquartile
limits 2.3; 9.0) and 1,984 with type 2
diabetes with 18,277 clinical measure-
ments followed for 3.7 years (1.0; 6.8).
In comparison with type 1 diabetes,
persons with type 2 diabetes were on
average 10 years older and more often of
male sex and were three times as likely to
be without any apparent retinopathy at
baseline (39% vs. 13%). For both type 1
and type 2 diabetes, close to half of the
study participants had normoalbuminu-
ria at baseline, which was associated
with a more favorable lipid profile, lower
levels of blood pressure and HbA1c, and a
higher age at diabetes diagnosis in com-
parison with those withmicro- or macro-
albuminuria (Tables 1 and 2). The degree
of antihypertensive treatment was com-
parable across groups of albuminuria
status. However, having normoalbumi-
nuria was associated with less frequent
use of RAS blockersdbut with more
frequent use of lipid-lowering medica-
tion. Difference in treatment across albu-
minuria status was especially pronounced
in type 1 diabetes. In people with type 1
diabetes, we also found a higher relative
difference in the proportion without any
retinopathy between the normo- and
macroalbuminuria group (20% vs. 4%)
compared with the group with type 2
diabetes (46% vs. 25%).
In the repeated longitudinal analysis,
we found for both type 1 and type 2
diabetes a significantly better fit with the
spline model compared with the model
including only a linear trend in eGFR over
time (P , 0.001). Therefore, time was
modeled using natural cubic splines with
knots set at 1, 3, and 6 years for type 1
diabetes and at 1, 2, and 5 years for type 2
diabetes. Albuminuria status significantly
modified the development in eGFR (P,
0.001) in both types of diabetes, with
the steepest decline in kidney function
among persons with macroalbuminuria
(Fig. 1). We found no modifying effect of
RAS blockers on the eGFR development
over time in any types of diabetes (P $
0.060). Because estimated eGFR trajec-
tories were similar for models 1 and
2 (Supplementary Fig. 1), only curves for
model 2 are shown. The estimated aver-
age annual decline in eGFR for normo-,
micro-, and macroalbuminuria the first
10 years following CKD3 was 1.9, 2.2, and
3.3 mL/min/1.73 m2 in type 1 diabetes
and 1.9, 2.1, and 2.9 mL/min/1.73 m2 in
type 2 diabetes (Supplementary Table 1).
In persons with normoalbuminuria, the
first recorded low eGFR was followed by
1 year of increasing eGFR of 1.6 mL/min/
1.73 m2 in both type 1 and type 2 diabetes
before eGFR again declined at an ap-
proximately linear rate. Among persons
with microalbuminuria, there was a sim-
ilar period of stable eGFR before an
approximately linear rate of decline in
eGFR occurred (Fig. 1).
In the sensitivity analysis following
persons from an eGFR ,70 mL/min/
1.73 m2, the trajectories were overall
similar in shape to those in Fig. 1 but
without a short-term increase in eGFR
(Supplementary Fig. 2).
From the LCTM approach among per-
sons with normoalbuminuria who were
also without albuminuria at baseline, the
two-class solutions were chosen for both
types of diabetes (for details on results
for 3-, 4-, or 5-class solutions see
Supplementary Tables 2 and 3 and
Supplementary Figs. 3 and 4). The two
distinct patterns of eGFR development
in type 1 and type 2 diabetes are shown
in Fig. 2.
For type 1 diabetes, themajority (class
1 [86%]) followed a pattern of eGFR
characterized by an initial increase and
then a steady linear decline. The second
and smaller class (class 2 [14%]) had a
steep decline in eGFR levels the first
4 years after entering CKD3, which
seemed to level off thereafter. At base-
line, class 2 had on average lower eGFR
values and a worse lipid profile and were
less likely in lipid-lowering treatment.
Members of class 1 were three times as
likely to be without any apparent reti-
nopathy (Table 3).
For type 2 diabetes, the majority (class
1 [90%]) followed a pattern of eGFR
characterized by an initial increase and
then a steady linear decline, resembling
that of the large class among type 1
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diabetes. The second and smaller class
(class 2 [10%]) had a steep decline in
eGFR the first 3 years after entering CKD3
and then a slight increase in eGFR. How-
ever, the median follow-up time in class
2 was only 2 years, which was half of that
in class 1. Furthermore, at the time of the
first eGFR measurement in CKD3, those
in class 2 were on average older with a
lower eGFR value but a better blood
pressure profile and with less antihyper-
tensive treatment. The lipid profile was
similar between the two classes despite
class 2 receiving less lipid-lowering treat-
ment and engaging in less regular exer-
cise. Persons in class 2 were less likely
to use RAS blockers. There was no
difference in retinopathy status, and in
both classes nearly halfwerewithout any
apparent retinopathy (Table 3).
CONCLUSIONS
For both types of diabetes, we found
eGFR levels to be on a progressive de-
clining trajectory when persons enter
CKD3. This was also true for persons
with normoalbuminuria, although with
a less steep decline in eGFR compared
with micro- and macroalbuminuria.
The estimated eGFR trajectories were
generally following a linear pattern,
which for the normoalbuminuric group
was true after an initial increase in eGFR.
Our findings were similar for type 1 and
type 2 diabetes. Previous studies have
shown diverging results on the linearity
of eGFR development. A previous anal-
ysis of the African American Study of
Kidney Disease and Hypertension (AASK)
trial found that almost 42% of the eGFR
trajectories were nonlinear, but this was
not a study exclusively including persons
with diabetes (8). Studies among persons
with diabetes or stratified by diabe-
tes status show a lower probability of
nonlinear eGFR trajectories (7,9,19).
Our study was additionally stratified
both by diabetes type and by albuminuria
status and further adjusted for various
time-varying confounders. Thismayhave
reduced the heterogeneity to a degree to
Table 1—Characteristics of the study population with type 1 diabetes in total and by albuminuria status at baseline
Total
Albuminuria status
Normoalbuminuria Microalbuminuria Macroalbuminuria
N 935 427 264 244
No. of clinical measurements 8 (4; 14) 7 (4; 12) 9 (5.0; 15.5) 10 (4; 18)
Follow-up time (years) 5.1 (2.3; 9.0) 5.2 (2.6; 9.0) 5.0 (2.5; 8.9) 5.1 (2.1; 9.0)
Age (years) 59.2 (14.5) 65.0 (12.5) 59.5 (13.4) 48.9 (13.2)
Male sex (%) 48.9 (45.6; 52.1) 37.2 (32.6; 42) 53.8 (47.6; 59.9) 63.9 (57.6; 70.0)
Age at diabetes diagnosis (years) 24.5 (12.1; 38.7) 31.0 (15.7; 45.8) 23.2 (11.8; 37.0) 14.5 (8.2; 27.8)
Diabetes duration (years) 31.7 (22.8; 41.3) 32.2 (22.6; 42.8) 34.6 (24.4; 42.6) 29.2 (22.6; 37)
HbA1c (%) 8.8 (1.4) 8.5 (1.3) 8.8 (1.4) 9.2 (1.5)
HbA1c (mmol/mol) 72.2 (15.4) 68.9 (13.9) 73.1 (15.2) 77.1 (16.6)
BMI (kg/m2) 25.3 (4.3) 25.4 (4.6) 25.1 (3.8) 25.4 (4.2)
eGFR (mL/min/1.73 m2) 53.3 (45.5; 57.1) 54.6 (48.4; 57.7) 53.0 (45.0; 57.0) 50.6 (36.2; 55.8)
UACR (mg/g) 45.5 (11.0; 334.0) 9.5 (5.0; 18.0) 89.0 (42.0; 209.0) 1,080 (487; 2,315)
Potassium (mmol/L) 4.3 (0.5) 4.3 (0.5) 4.4 (0.5) 4.3 (0.6)
Sodium (mmol/L) 138.0 (3.6) 138.4 (3.3) 137.6 (3.8) 137.7 (3.6)
Systolic blood pressure (mmHg) 139.8 (21.0) 137.8 (20.0) 138.6 (22.5) 144.6 (20.3)
Diastolic blood pressure (mmHg) 75.0 (11.3) 72.8 (10.3) 74.0 (11.3) 80.3 (11.4)
Total cholesterol (mmol/L) 5.1 (1.2) 5.1 (1.1) 4.9 (1.1) 5.5 (1.3)
HDL cholesterol (mmol/L) 1.7 (0.6) 1.8 (0.6) 1.7 (0.6) 1.6 (0.6)
LDL cholesterol (mmol/L) 2.7 (0.9) 2.7 (0.9) 2.5 (0.9) 3.1 (1.0)
Triglycerides (mmol/L) 1.2 (0.9; 1.8) 1.1 (0.8; 1.6) 1.2 (0.9; 1.8) 1.5 (1.0; 2.2)
RAS blockers (%) 62.8 (59.6; 65.9) 59.5 (54.7; 64.2) 62.1 (56.0; 68.0) 69.3 (63.1; 75.0)
Antihypertensive treatment (%) 79.8 (77.1; 82.3) 78.0 (73.8; 81.8) 81.1 (75.8; 85.6) 81.6 (76.1; 86.2)
Lipid-lowering medication (%) 43.7 (40.5; 47) 46.4 (41.6; 51.2) 45.8 (39.7; 52.1) 36.9 (30.8; 43.3)
Retinopathy status (%)
No apparent retinopathy 13.0 (10.7; 15.7) 20.0 (16.0; 24.5) 9.0 (5.5; 13.8) 3.9 (1.6; 7.8)
Mild/moderate retinopathy 22.8 (19.9; 26.0) 28.7 (24.1; 33.7) 22.9 (17.4; 29.1) 11.1 (6.9; 16.6)
Severe retinopathy 64.2 (60.6; 67.6) 51.3 (45.9; 56.6) 68.1 (61.3; 74.3) 85.0 (78.9; 89.9)
Smoking (%)
No 55.4 (51.3; 59.5) 62.2 (56.5; 67.6) 53.3 (45.4; 61.0) 40.4 (31.3; 49.9)
Previous 2.7 (1.6; 4.4) 3.3 (1.6; 6.0) 1.8 (0.4; 5.2) 2.6 (0.5; 7.5)
Yes 41.9 (37.8; 46.0) 34.5 (29.2; 40.2) 44.9 (37.2; 52.8) 57.0 (47.4; 66.3)
Alcohol intake (units/week)*
0 14.0 (11.2; 17.1) 12.0 (8.5; 16.2) 13.1 (8.3; 19.4) 20.5 (13.5; 29.2)
1–20 75.0 (71.2; 78.5) 80.0 (75; 84.4) 71.3 (63.6; 78.1) 67.0 (57.4; 75.6)
.20 11.0 (8.6; 13.9) 8.0 (5.2; 11.7) 15.6 (10.4; 22.2) 12.5 (7.0; 20.1)
Regular exercise (%)† 57.7 (53.5; 61.7) 62.7 (56.9; 68.2) 50.9 (42.9; 58.9) 54.0 (44.4; 63.4)
Data are mean (SD), median (interquartile limits), or proportion (95% CI). *A unit of alcohol: 12 g pure alcohol. †Regular exercise:$30 min per day.
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which the mean estimated eGFR trajec-
tories were overall linear.
However, we did find some degree of
heterogeneity in eGFR development
among persons with normoalbuminuria
and CKD3, with most persons showing
an initial improvement in kidney func-
tion before further decline in eGFR. This
short-term increase in eGFR is in line
with two recent studies in an Indigenous
Australian population at high risk of CKD
(20) and in a Chinese population with
type 2 diabetes (21) and may be a conse-
quence of intensified treatment follow-
ing a clinical classification of moderate
loss of kidney function. We found no
short-term improvement in eGFR in the
sensitivity analysis following persons
from an eGFR ,70 mL/min/1.73 m2,
which in itself does not indicate loss
of kidney function (Supplementary Fig.
2). We therefore believe the short-term
increase in eGFR among persons with
normoalbuminuria and CKD3 in our study
to be a treatment effect rather than a
regression-to-the-mean phenomenon.
Among persons with diabetes with
CKD3 and normoalbuminuria, it appears
that the observed decline in eGFR in the
first 3–4 years following baseline to a
large extent is driven by a small group
with accelerated declining eGFR levels.
This specific progression pattern was
associated with less use of lipid-lowering
treatment, RAS blocking, and other an-
tihypertensive treatment. Although in-
terpretation of such observational data
should always be done with caution,
our results indicate that this group is
somehow overlooked and insufficiently
risk stratified. One obvious reason for
this relates to the use of albuminuria
rather than eGFR in the clinic to identify
persons at high risk for diabetic kidney
disease with a recommendation to
intensify glucose-, lipid-, and blood
pressure–lowering treatment. For type
2 diabetes, the lower levels of blood
pressure (and borderline lower levels
of LDL cholesterol) may also contribute
to a lower perceived cardiometabolic risk.
Table 2—Characteristics of the study population with type 2 diabetes in total and by albuminuria status at baseline
Total
Albuminuria status
Normoalbuminuria Microalbuminuria Macroalbuminuria
N 1,984 942 664 378
No. of clinical measurements 7 (3; 12) 6 (3; 10) 7 (4; 13) 7 (3; 14)
Follow-up time (years) 3.7 (1.0; 6.8) 3.6 (0.9; 6.6) 4.3 (1.3; 7.4) 3.2 (1.0; 6.4)
Age (years) 69.3 (9.3) 70.5 (8.5) 69.5 (9.3) 66.1 (10.5)
Males (%) 57.6 (55.3; 59.7) 47.7 (44.5; 51) 64.0 (60.2; 67.7) 70.7 (65.8; 75.2)
Age at diabetes diagnosis (years) 55.7 (47.4; 63.4) 57.4 (49.9; 64.7) 55.3 (47.2; 63.3) 51.3 (43.7; 59.6)
Diabetes duration (years) 13.4 (7.8; 19.3) 12.8 (7.6; 18.9) 13.6 (7.8; 19.7) 14.5 (8.7; 19.6)
HbA1c (%) 8.2 (1.6) 8.1 (1.6) 8.3 (1.7) 8.6 (1.7)
HbA1c (mmol/mol) 66.5 (17.8) 64.6 (17) 67.4 (18.3) 70.0 (18.3)
BMI (kg/m2) 30.5 (5.7) 30.4 (5.6) 30.5 (5.7) 30.7 (5.7)
eGFR (mL/min/1.73 m2) 52.4 (43.9; 57.1) 53.5 (45.5; 57.4) 51.7 (43.8; 57.1) 50.7 (38.5; 56.5)
UACR (mg/g) 34.5 (9.0; 176.0) 9.0 (5.0; 17.0) 87.0 (46.5; 165.0) 779.5 (404; 1,670)
Potassium (mmol/L) 4.3 (0.5) 4.3 (0.5) 4.3 (0.5) 4.3 (0.5)
Sodium (mmol/L) 139.0 (3.5) 139.2 (3.5) 139.0 (3.6) 138.8 (3.4)
Systolic blood pressure (mmHg) 141.3 (22.3) 136.8 (21.0) 141.7 (21.5) 151.6 (23.7)
Diastolic blood pressure (mmHg) 75.4 (11.8) 73.8 (11.2) 75.7 (11.7) 79.2 (12.6)
Total cholesterol (mmol/L) 4.7 (1.3) 4.6 (1.2) 4.6 (1.2) 5.1 (1.5)
HDL cholesterol (mmol/L) 1.2 (0.4) 1.3 (0.4) 1.2 (0.4) 1.2 (0.4)
LDL cholesterol (mmol/L) 2.5 (1.1) 2.4 (1.0) 2.4 (1.0) 2.8 (1.3)
Triglycerides (mmol/L) 1.9 (1.4; 2.9) 1.8 (1.3; 2.7) 2.0 (1.4; 3.0) 2.2 (1.6; 3.2)
RAS blockers (%) 55.2 (53.0; 57.4) 52.4 (49.1; 55.6) 58.9 (55.0; 62.7) 55.7 (50.5; 60.7)
Antihypertensive treatment (%) 72.1 (70.1; 74.1) 70.2 (67.2; 73.1) 75.6 (72.2; 78.8) 70.7 (65.8; 75.2)
Lipid-lowering medication (%) 50.6 (48.4; 52.8) 51.5 (48.3; 54.8) 50.9 (47.0; 54.8) 47.8 (42.6; 52.9)
Retinopathy status (%)
No apparent retinopathy 38.6 (36.2; 40.9) 46.4 (42.9; 49.9) 34.9 (30.9; 39.0) 25.2 (20.5; 30.4)
Mild/moderate retinopathy 25.1 (23.0; 27.2) 24.9 (22.0; 28.1) 27.8 (24.1; 31.7) 20.4 (16.1; 25.3)
Severe retinopathy 36.4 (34.1; 38.7) 28.7 (25.6; 31.9) 37.3 (33.3; 41.5) 54.3 (48.6; 59.9)
Smoking (%)
No 61.5 (58.8; 64.1) 65.4 (61.7; 69.0) 60.5 (55.8; 65.1) 51.4 (44.6; 58.1)
Previous 4.5 (3.5; 5.8) 3.3 (2.1; 5.0) 6.1 (4.1; 8.7) 5.0 (2.5; 8.7)
Yes 34.0 (31.5; 36.6) 31.3 (27.8; 34.9) 33.4 (29.0; 38.0) 43.7 (37.1; 50.5)
Alcohol intake (units/week)*
0 21.4 (19.2; 23.7) 19.6 (16.6; 22.7) 22.1 (18.3; 26.3) 25.6 (19.9; 32)
1–20 71.5 (69.0; 73.9) 74.7 (71.3; 77.9) 68.7 (64.1; 73.0) 67.0 (60.3; 73.2)
.20 7.1 (5.8; 8.7) 5.7 (4.1; 7.8) 9.2 (6.7; 12.3) 7.4 (4.3; 11.8)
Regular exercise (%)† 42.2 (39.6; 45.0) 43.8 (40.1; 47.7) 41.4 (36.7; 46.2) 38.8 (32.2; 45.7)
Data are mean (SD), median (interquartile limits), or proportion (95% CI). *A unit of alcohol: 12 g pure alcohol. †Regular exercise:$30 min per day.
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In comparison with micro- or macroal-
buminuria, normoalbuminuria was asso-
ciated with a higher proportion of no
retinopathy in both types of diabetes,
possibly reflecting a harmless subtype
of nephropathy caused by risk factors
other than diabetes (5,6). However, we
found no difference in the rate of eGFR
decline between persons with and with-
out any retinopathy (P $ 0.168 [data not
shown]). Among our study participants,
240 (7.8%) progressed to CKD stage 5
(CKD5), defined as eGFR ,15 mL/min/
1.73 m2. While 81% had developed
macroalbuminuria before CKD5, nearly
one in five had not, suggesting that tran-
sition to macroalbuminuria is not a pre-
requisite for developing kidney failure
defined by CKD5. There is ongoing
discussion regarding the potential exis-
tence of a specific nonalbuminuric ne-
phropathy phenotype in type 2 diabetes,
but further exploration into structural
differences would require a prospective
renal biopsy cohort study combinedwith
functional investigations to establish the
existence of such a phenotype.
We found RAS blocking treatment to
modify the eGFR decline in type 2 but not
in type 1 diabetes. The randomized con-
trolled trials showing benefits of RAS
blocking treatment in type 2 diabetes
have been conducted in high-risk pop-
ulations with hypertension and macro-
albuminuria, mostly using composite
categorical outcome and not decline in
kidney function over time (22). Studies
are rarely long enough (.2 years of
follow-up) to assess impact on eGFR,
and so our study represents one of
the few longtime assessments of the
modifying effect of RAS blocking treat-
ment. It is, however, important to re-
member that initiation of RAS blocking
treatment may cause an acute decline in
eGFR while subsequently stabilizing to a
lesser rate of eGFR decline. Among our
study participants with albuminuria, ini-
tiation of treatment with RAS blockers
could have occurred prior to study base-
line, which may explain the inability to
demonstrate a clinically relevant effect
of RAS blocking on eGFR decline in the
current study.
Clinical Perspective
In general, the annual age-related decline
in eGFR from age 40 years is believed to
be 1 mL/min/1.73 m2 in the background
populationwithout CKD (23–25) down to
0.4 mL/min/1.73 m2 in a healthy pop-
ulation of white ethnicity and without
diabetes (26). The decline in persons with
normoalbuminuria in our cohort is higher
at ;1.9 mL/min/1.73 m2 per year, most
likely because CKD3 is reflecting some
formof renal disease. Even after removal
of eGFR measurements after periods
with albuminuria in this subpopulation,
the annual decline was still 1.4 mL/min/
1.73 m2 (data not shown). We have,
however, not been able to investigate
whether acute kidney injury preceded
the development of CKD3. The propor-
tion of normoalbuminuric participants
with an early progressive eGFR decline
was 14% in type 1 diabetes and 10% in
type 2 diabetes (Fig. 2), which was some-
what higher than the 9% found in type 1
diabetes in the study by Perkins et al. (27).
The higher proportion found in our study
may be explained by the fact that par-
ticipants with type 1 diabetes from the
Joslin Diabetes Center were younger and
healthier, including having much higher
levels of eGFR at study entry. From a
clinical perspective, it is comforting that
most persons in a contemporary tertiary
clinic preserve low annual decline in eGFR
after development of CKD3. This is es-
pecially important in the groups with
albuminuria, which had low annual de-
cline (between 2.1 and 3.3 mL/min/
1.73 m2 per year) in eGFR compared
with historical cohorts displaying much
higher annual declines (;10–20 mL/
min/1.73 m2 per year) (28–30). In line
with the improvements seen in eGFR
Figure 1—Estimated eGFR trajectories by diabetes type and albuminuria status for persons with
a first recorded low eGFR just below 60 mL/min/1.73 m2. Time 0 is the first clinical visit with
a recorded low eGFR. Curves are shown for persons with normoalbuminuria (light blue),
microalbuminuria (dark blue), or macroalbuminuria (red) with differences adjusted for sex,
age at diabetes diagnosis, diabetes duration, calendar time, use of RAS blockers, retinopathy
status, HbA1c, antihypertensive treatment, blood pressure, current smoking, and lipid-lowering
treatment. Solid lines are the estimated eGFR mean curves, and shaded areas are the
corresponding 95% CIs. Horizontal gray lines show the thresholds for CKD stages.
Figure 2—Estimated eGFR trajectories for the subset of persons with normoalbuminuria whowere also
without albuminuria at baseline for those with a first recorded low eGFR just below 60mL/min/1.73 m2.
Time 0 is the first clinical visit with a recorded low eGFR. Curves are shown for the most frequent
normoalbuminuric trajectory in black (86% and 90% for type 1 and 2 diabetes, respectively) and for
the infrequent normoalbuminuric trajectory in gray (14% and 10% for type 1 and 2 diabetes) with
differences adjusted for calendar time. Solid lines are the estimated eGFR mean curves, and shaded
areas are the corresponding 95% CIs. Horizontal gray lines show the thresholds for CKD stages.
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decline, the incidence of ESKD in Danish
persons has stabilized during recent
years despite an increasing number of
persons with diabetes (31).
Previous studies have demonstrated
large variation in eGFR progression in
persons with diabetes. Our study shows
that this also applies after the manifes-
tation of moderate loss of kidney func-
tion (CKD3), even among persons with
normoalbuminuria, where some are al-
ready on an accelerated declining eGFR
trajectory. It is important to identify
these persons to prevent further loss
of renal function and associated com-
plications such as end-stage renal dis-
ease. Regular assessment of albuminuria
and eGFR should therefore be per-
formed as recommended in current
guidelines (3), and ideally individual-
ized risk assessment models should be
developed.
Strengths and Limitations
A major strength of the study relates to
the large single-center longitudinal data
set with repeated detailed clinical mea-
sures and a follow-up of 16 years. This
enabled us to account for change over
time in covariates such as treatment and
to relate trajectories of eGFR develop-
ment according to degree of albuminuria
for persons with diabetes entering CKD3.
With the use of cubic splines to model
development over time, wewere further
able to detect temporal changes in eGFR
levels, such as the initial improvement
we found in normoalbuminuria.
A single low eGFR was used as in-
clusion criteria in our study. Other stud-
ies have used sustained low eGFR (5,32)
to increase the likelihood of the study
Table 3—Characteristics of the latent class trajectory classes by diabetes type at baseline
Type 1 diabetes Type 2 diabetes
Class 1 Class 2 P Class 1 Class 2 P
N (%) 342 (86) 55 (14) 769 (90) 88 (10)
No. of clinical measurements 5.0 (3; 9) 7.0 (4; 10) 0.021 5 (3; 8) 5 (3; 8) 0.762
Follow-up time (years) 5.3 (2.6; 9.1) 5.8 (3.2; 9.6) 0.640 4.1 (1.0; 6.8) 2.0 (0.8; 5.4) 0.027
Age (years) 65.0 (12.1) 66.8 (12.0) 0.297 69.8 (8.5) 73.9 (7.4) ,0.001
Male sex (%) 36.5 (31.4; 41.9) 34.5 (22.2; 48.6) 0.773 48.0 (44.4; 51.6) 39.8 (29.5; 50.8) 0.142
Age at diabetes diagnosis (years) 30.7 (15.2; 46.6) 32.3 (17.4; 40.0) 0.392 57.0 (49.4; 63.9) 59.9 (52.2; 69.7) 0.002
Diabetes duration (years) 31.9 (22.7; 43.2) 35.2 (25.8; 42.8) 0.597 12.7 (7.6; 18) 12.5 (5.7; 19.6) 0.706
HbA1c (%) 8.4 (1.3) 8.6 (1.4) 0.352 8.1 (1.5) 7.7 (1.3) 0.059
HbA1c (mmol/mol) 68.7 (13.7) 70.6 (15.7) 0.352 64.7 (16.8) 61.2 (14.8) 0.059
Height (cm) 169.7 (9.1) 170.8 (8.7) 0.408 169.4 (10.0) 167.8 (9.8) 0.155
BMI (kg/m2) 25.5 (4.6) 25.3 (4.6) 0.718 30.4 (5.6) 30.6 (5.2) 0.781
eGFR (mL/min/1.73 m2) 55.6 (51.6; 58.1) 44.0 (35.4; 48.7) ,0.001 54.5 (49.1; 57.6) 33.9 (27.5; 39.5) ,0.001
UACR (mg/g) 8.0 (5.0; 16.0) 11.0 (6.0; 25.0) 0.031 8.0 (5.0; 17.0) 9.0 (5.0; 17.0) 0.821
Potassium (mmol/L) 4.3 (0.5) 4.3 (0.6) 0.466 4.3 (0.5) 4.4 (0.5) 0.013
Sodium (mmol/L) 138.4 (3.3) 138.1 (3.6) 0.644 139.2 (3.3) 139.6 (4.2) 0.313
Systolic blood pressure (mmHg) 137.3 (19.9) 142.6 (21.0) 0.074 136.9 (20.7) 131.5 (22.0) 0.021
Diastolic blood pressure (mmHg) 72.8 (10.4) 72.3 (10.1) 0.762 74.1 (11.1) 70.1 (12.5) 0.002
Total cholesterol (mmol/L) 5.0 (1.0) 5.4 (1.5) 0.011 4.6 (1.1) 4.5 (1.5) 0.336
HDL cholesterol (mmol/L) 1.8 (0.6) 1.6 (0.4) 0.009 1.3 (0.4) 1.2 (0.4) 0.055
LDL cholesterol (mmol/L) 2.6 (0.8) 3.1 (1.1) ,0.001 2.4 (1.0) 2.2 (1.0) 0.050
Triglycerides (mmol/L) 1.1 (0.8; 1.6) 1.3 (0.9; 1.8) 0.114 1.8 (1.3; 2.6) 1.9 (1.4; 2.9) 0.145
RAS blockers (%) 58.8 (53.4; 64.0) 67.3 (53.3; 79.3) 0.228 55.0 (51.4; 58.6) 42.0 (31.6; 53.0) 0.021
Antihypertensive treatment (%) 77.5 (72.7; 81.8) 85.5 (73.3; 93.5) 0.165 72.2 (68.9; 75.3) 56.8 (45.8; 67.3) 0.004
Lipid-lowering medication (%) 49.4 (44; 54.8) 34.5 (22.2; 48.6) 0.039 54.6 (51.0; 58.2) 39.8 (29.5; 50.8) 0.008
Retinopathy status (%)
No apparent retinopathy 22.3 (17.7; 27.5) 7.3 (1.5; 19.9) 0.014 47.4 (43.6; 51.3) 47.0 (34.6; 59.7) 0.946
Mild/moderate retinopathy 29.7 (24.6; 35.2) 19.5 (8.8; 34.9) 0.162 24.3 (21.1; 27.7) 27.3 (17.0; 39.6) 0.596
Severe retinopathy 48.0 (42.2; 53.8) 73.2 (57.1; 85.8) 0.002 28.3 (24.9; 31.9) 25.8 (15.8; 38.0) 0.659
Smoking (%)
No 61.8 (55.6; 67.7) 61.5 (40.6; 79.8) 0.981 65.0 (61.0; 68.9) 72.9 (59.7; 83.6) 0.219
Previous 3.5 (1.6; 6.5) 0.0 (0.0; 13.2) 0.186 3.7 (2.3; 5.5) 1.7 (0.0; 9.1) 0.391
Yes 34.7 (29.0; 40.9) 38.5 (20.2; 59.4) 0.707 31.3 (27.5; 35.3) 25.4 (15; 38.4) 0.344
Alcohol intake (units/week)*
0 11.6 (8.0; 16.2) 4.3 (0.1; 21.9) 0.234 18.6 (15.5; 22.0) 19.6 (10.2; 32.4) 0.849
1–20 79.8 (74.4; 84.6) 91.3 (72.0; 98.9) 0.146 75.3 (71.5; 78.8) 78.6 (65.6; 88.4) 0.577
.20 8.5 (5.4; 12.6) 4.3 (0.1; 21.9) 0.448 6.1 (4.3; 8.4) 1.8 (0.0; 9.6) 0.125
Regular exercise (%)† 64.6 (58.4; 70.4) 54.2 (32.8; 74.4) 0.316 46.2 (42.1; 50.4) 25.9 (15.3; 39.0) 0.002
Data are mean (SD), median (interquartile limits), or proportion (95% CI). P is the level of significance for the unadjusted test of overall difference
between classes, using t tests for difference in means or log(means) and x2 tests for difference in proportions. *A unit of alcohol: 12 g pure alcohol.
†Regular exercise: $30 min per day.
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population being truly renal insufficient.
We chose this approach to maximize
power but mainly to facilitate the study
of heterogeneity in eGFR development
among persons with normoalbuminuria.
Typically, trajectories of eGFR have
been investigated for the total group
with normoalbuminuria, which may
oversimplify the heterogeneous progres-
sion patterns preceding diabetic kidney
disease. We used LCTM to find subgroups
with distinct eGFR growth patterns
among persons with normoalbuminuria.
The LCTM approach has the advantage of
being hypothesis free, thus enabling the
identification of heterogeneity in eGFR
development that would not be identi-
fiedbyuseof conventionalmethods.One
disadvantage of LCTM is, however, that
some subgroups tend to be very small,
potentially limiting statistical power as
well as generalizability of the results.
Furthermore, for the normoalbuminuric
class 2 with progressive declining eGFR
levels, follow-up timewas short, and due
to competing risk from mortality (33),
the long-term trajectory of eGFR may
reflect a healthy survivor bias. However,
similar patterns have been found in a
study of African Americans with multiple
eGFR measurements over a median of
9 years of follow-up (8).
There are other study limitations. First,
in around half of the clinical examinations,
albuminuria status was based on a single
spot urine from first morning void rather
than on 24-h urinary albumin excretion.
This could potentially have resulted in
some misclassification (34). Second, glo-
merular filtration rate was estimated and
not measured directly, which may involve
some degree of imprecision to the trajec-
tories. Third, while the population with
type 1 diabetes is representative of the
general Danish population with type 1 di-
abetes, the population with type 2 di-
abetes has relatively advanced disease
and often significant late diabetes com-
plications. The relatively advanced dis-
ease state in our population with
type 2 diabetes may partly explain why
we found a higher annual eGFR decline
among those with normoalbuminuria
than in a recent study on the younger
and healthier Chronic Renal Insufficiency
Cohort (CRIC), which showed a decline of
only 0.17 mL/min/1.73 m2 per year (35).
Another factor that could explain the
discrepancy is that the CRIC study used
an internal glomerular filtration rate–
estimating equation and eGFR levels up
to 70 mL/min/1.73 m2 were used as entry
criteria in the younger age-groups (,45
years old). Lastly, because the population
with diabetes in this study is predominantly
of Danish ancestry (.90%), extrapolating
results to nonwhite ethnicities should
be done with caution.
Conclusion
Our results support a diabetes-dependent
decline in kidney function without albu-
minuria following CKD3, and among these
individuals, a subgroup shows a progres-
sive decline. Furthermore, this group
seems to be somehow undertreated in
terms of cardioprotective and renal pro-
tective treatment, which suggests that
increased attention should be drawn to
normoalbuminuric diabetic kidney disease.
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